Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 14/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051428 | 0.90 | GPR119 (0.39) | GPR119HPGD | |
| SCHEMBL4052440 | 0.88 | RBP4 (0.40) | HPGD | |
| SCHEMBL4050096 | 0.87 | RAB9A (0.45) | GPR119ALDH1A1HPGDKDM4E | |
| SCHEMBL4054769 | 0.86 | GPR119 (0.39) | GPR119TLR8TLR7TLR9HPGD | |
| SCHEMBL13691397 | 0.86 | GPR119 (0.53) | GPR119 | |
| SCHEMBL4562706 | 0.86 | GPR119 (0.53) | GPR119 | |
| SCHEMBL4056519 | 0.85 | TRPC6 (0.40) | SLC6A7TLR8TLR7ALDH1A1TSHR | |
| SCHEMBL13691402 | 0.75 | GPR119 (0.56) | GPR119 | |
| SCHEMBL4052686 | 0.74 | TRPC6 (0.42) | — | |
| SCHEMBL4355713 | 0.74 | SLC6A7 (0.44) | SLC6A7GPR119ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |